The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy
暂无分享,去创建一个
Yanmei Xu | Jing Liu | Bo Huang | Jin Lin | Jing Zhang | Junyao Jiang | Xiaozhong Wang | Shuqi Li | Fangmin Zhong | Meiyong Li | Ying Cheng | Shuai Xu | Fangyi Yao
[1] E. Jabbour,et al. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase , 2022, Journal of Hematology & Oncology.
[2] A. Tiwari,et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond , 2022, Molecular cancer.
[3] J. Doroshow,et al. PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components , 2022, OncoTargets and therapy.
[4] G. Martinelli,et al. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies , 2022, Journal of Hematology & Oncology.
[5] L. Pang,et al. Detailed resume of RNA m6A demethylases , 2022, Acta pharmaceutica Sinica. B.
[6] O. Grzybowska-Izydorczyk,et al. The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program , 2021, Clinical Lymphoma Myeloma and Leukemia.
[7] S. Javed,et al. A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs , 2021, Frontiers in Genetics.
[8] K. Flynn,et al. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions , 2021, Current Hematologic Malignancy Reports.
[9] W. Wang,et al. Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification. , 2021, Bone.
[10] Jianying Zhou,et al. VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. , 2021, Cancer letters.
[11] Zheng-lan Huang,et al. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells , 2021, Journal of Hematology & Oncology.
[12] B. Pang,et al. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma , 2021, Journal of Hematology & Oncology.
[13] C. Tisné,et al. A comprehensive review of m6A/m6Am RNA methyltransferase structures , 2021, Nucleic acids research.
[14] Andrew J. Bannister,et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia , 2021, Nature.
[15] Ji-Fu Wei,et al. Role of m6A methyltransferase component VIRMA in multiple human cancers (Review) , 2021, Cancer cell international.
[16] Jun Zhou,et al. Differential roles of YTHDF1 and YTHDF3 in embryonic stem cell-derived cardiomyocyte differentiation , 2020, RNA biology.
[17] C. Schiffer,et al. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? , 2020, Haematologica.
[18] Samie R. Jaffrey,et al. A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA , 2020, Cell.
[19] Keqiu Jiang,et al. Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. , 2020, Carcinogenesis.
[20] W. Xie,et al. m6A-binding proteins: the emerging crucial performers in epigenetics , 2020, Journal of Hematology & Oncology.
[21] B. Druker,et al. Response and Resistance to BCR-ABL1-Targeted Therapies. , 2020, Cancer cell.
[22] Jianjun Chen,et al. m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.
[23] Ming-Hai Wang,et al. KIAA1429 regulates cell proliferation by targeting c‐Jun messenger RNA directly in gastric cancer , 2020, Journal of cellular physiology.
[24] Katya Frazier,et al. Emerging role of m6A RNA methylation in nutritional physiology and metabolism , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[25] Jianjun Chen,et al. The Biogenesis and Precise Control of RNA m6A Methylation. , 2019, Trends in genetics : TIG.
[26] Shiqing Ma,et al. Epigenetic Regulation of m6A Modifications in Human Cancer , 2019, Molecular therapy. Nucleic acids.
[27] A. Tefferi,et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management , 2019, American journal of hematology.
[28] Mengda Cao,et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner , 2019, Oncogene.
[29] Liang Wang,et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA , 2019, OncoTargets and therapy.
[30] Chuan He,et al. Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. , 2019, Molecular cell.
[31] A. Fatica,et al. N6-Methyladenosine (m6A): A Promising New Molecular Target in Acute Myeloid Leukemia , 2019, Front. Oncol..
[32] Hualiang Jiang,et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.
[33] R. Flavell,et al. RNA m6A modification and its function in diseases , 2018, Frontiers of Medicine.
[34] Chuan He,et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation , 2018, Cell Discovery.
[35] G. Martinelli,et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy , 2018, Molecular Cancer.
[36] Hao Zhou,et al. miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding , 2018, Leukemia.
[37] Yue Sheng,et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. , 2017, Cell stem cell.
[38] John E. J. Rasko,et al. Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia , 2017, Journal of Hematology & Oncology.
[39] P. Ren,et al. Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer. , 2016, Oncology letters.
[40] J. Dengjel,et al. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells , 2016, Cell Communication and Signaling.
[41] R. Xu,et al. Leukemia stem cells: the root of chronic myeloid leukemia , 2015, Protein & Cell.
[42] Schraga Schwartz,et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. , 2014, Cell reports.
[43] Jinhui Wang,et al. ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2014, PLoS Genetics.
[44] M. Fukuda. Rab27 Effectors, Pleiotropic Regulators in Secretory Pathways , 2013, Traffic.
[45] S. Hamm-Alvarez,et al. Direct Imaging of RAB27B-Enriched Secretory Vesicle Biogenesis in Lacrimal Acinar Cells Reveals Origins on a Nascent Vesicle Budding Site , 2012, PloS one.
[46] N. Udagawa,et al. Rab27a and Rab27b are involved in stimulation‐dependent RANKL release from secretory lysosomes in osteoblastic cells , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[47] M. Fukuda,et al. The small GTPase Rab27B regulates amylase release from rat parotid acinar cells , 2004, Journal of Cell Science.
[48] R. Burbano,et al. Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model , 2021, In Vivo.
[49] T. Lion,et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. , 2021, American journal of cancer research.
[50] Shaoguang Li,et al. Leukemia Stem Cells in Chronic Myeloid Leukemia. , 2019, Advances in experimental medicine and biology.